BCYC
Price
$7.47
Change
+$0.30 (+4.18%)
Updated
Jul 8, 04:59 PM (EDT)
Capitalization
519.4M
22 days until earnings call
STRO
Price
$0.78
Change
+$0.04 (+5.41%)
Updated
Jul 8, 04:59 PM (EDT)
Capitalization
66.26M
30 days until earnings call
Interact to see
Advertisement

BCYC vs STRO

Header iconBCYC vs STRO Comparison
Open Charts BCYC vs STROBanner chart's image
Bicycle Therapeutics
Price$7.47
Change+$0.30 (+4.18%)
Volume$2.26K
Capitalization519.4M
Sutro Biopharma
Price$0.78
Change+$0.04 (+5.41%)
Volume$3.74K
Capitalization66.26M
BCYC vs STRO Comparison Chart in %
Loading...
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCYC vs. STRO commentary
Jul 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Buy and STRO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 09, 2025
Stock price -- (BCYC: $7.50 vs. STRO: $0.78)
Brand notoriety: BCYC and STRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 68% vs. STRO: 30%
Market capitalization -- BCYC: $519.4M vs. STRO: $66.26M
BCYC [@Biotechnology] is valued at $519.4M. STRO’s [@Biotechnology] market capitalization is $66.26M. The market cap for tickers in the [@Biotechnology] industry ranges from $309.49B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 1 FA rating(s) are green whileSTRO’s FA Score has 1 green FA rating(s).

  • BCYC’s FA Score: 1 green, 4 red.
  • STRO’s FA Score: 1 green, 4 red.
According to our system of comparison, both BCYC and STRO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 5 TA indicator(s) are bullish while STRO’s TA Score has 4 bullish TA indicator(s).

  • BCYC’s TA Score: 5 bullish, 5 bearish.
  • STRO’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, BCYC is a better buy in the short-term than STRO.

Price Growth

BCYC (@Biotechnology) experienced а +6.69% price change this week, while STRO (@Biotechnology) price change was +15.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.39%. For the same industry, the average monthly price growth was +14.41%, and the average quarterly price growth was +12.94%.

Reported Earning Dates

BCYC is expected to report earnings on Oct 30, 2025.

STRO is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+9.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCYC($519M) has a higher market cap than STRO($66.3M). BCYC YTD gains are higher at: -46.429 vs. STRO (-59.739). BCYC (-200.61M) and STRO (-203.18M) have comparable annual earnings (EBITDA) . BCYC has more cash in the bank: 793M vs. STRO (249M). BCYC has less debt than STRO: BCYC (8.33M) vs STRO (21.4M). STRO has higher revenues than BCYC: STRO (66.4M) vs BCYC (25.7M).
BCYCSTROBCYC / STRO
Capitalization519M66.3M783%
EBITDA-200.61M-203.18M99%
Gain YTD-46.429-59.73978%
P/E RatioN/AN/A-
Revenue25.7M66.4M39%
Total Cash793M249M318%
Total Debt8.33M21.4M39%
FUNDAMENTALS RATINGS
BCYC vs STRO: Fundamental Ratings
BCYC
STRO
OUTLOOK RATING
1..100
7450
VALUATION
overvalued / fair valued / undervalued
1..100
20
Undervalued
26
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
6565
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
3085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (20) in the null industry is in the same range as STRO (26) in the Pharmaceuticals Major industry. This means that BCYC’s stock grew similarly to STRO’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as STRO (100) in the Pharmaceuticals Major industry. This means that BCYC’s stock grew similarly to STRO’s over the last 12 months.

BCYC's SMR Rating (96) in the null industry is in the same range as STRO (100) in the Pharmaceuticals Major industry. This means that BCYC’s stock grew similarly to STRO’s over the last 12 months.

BCYC's Price Growth Rating (65) in the null industry is in the same range as STRO (65) in the Pharmaceuticals Major industry. This means that BCYC’s stock grew similarly to STRO’s over the last 12 months.

BCYC's P/E Growth Rating (100) in the null industry is in the same range as STRO (100) in the Pharmaceuticals Major industry. This means that BCYC’s stock grew similarly to STRO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCYCSTRO
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 7 days ago
82%
Bullish Trend 15 days ago
81%
Declines
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GLESX13.620.03
+0.22%
GS Energy Infrastructure Fd R6 Shares
FBTCX20.46N/A
N/A
Fidelity Advisor Biotechnology C
ANONX23.13N/A
N/A
American Century Small Cap Growth I
ABAEX9.36N/A
N/A
AB Emerging Markets Multi-Asset A
UPAAX14.94N/A
N/A
Upright Assets Allocation Plus

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with XNCR. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
+4.60%
XNCR - BCYC
54%
Loosely correlated
+4.16%
RPTX - BCYC
51%
Loosely correlated
+7.75%
RLAY - BCYC
50%
Loosely correlated
+1.13%
INO - BCYC
48%
Loosely correlated
+0.75%
RCUS - BCYC
45%
Loosely correlated
+3.41%
More

STRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, STRO has been loosely correlated with ALGS. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if STRO jumps, then ALGS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STRO
1D Price
Change %
STRO100%
-2.94%
ALGS - STRO
44%
Loosely correlated
-4.34%
PDSB - STRO
40%
Loosely correlated
-8.27%
TRDA - STRO
40%
Loosely correlated
-3.60%
TCRX - STRO
40%
Loosely correlated
-3.97%
ATXS - STRO
40%
Loosely correlated
+6.71%
More